 WATERTOWN, Mass. , Aug. 29, 2022 PRNewswire -- Lyra Therapeutics, Inc. Nasdaq: LYRA, a clinical-stage therapeutics company leveraging its proprietary XTreoTM platform to enable precise, sustained and local delivery of medications to the ear, nose and throat ENT passages and other diseased tissues, today announced that the company will present additional Phase 2 results from the LANTERN study for LYR210, the companys lead product candidate for chronic rhinosinusitis, at the 68th Annual Meeting of the American Rhinologic Society ARS, taking place September 9-10, 2022 in Philadelphia. 